Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01858519 · ClinicalTrials.gov registry record
Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement Therapy
A clinical trial, sponsored by AbbVie.
- Completed
- Registry status
- 1,310
- Enrollment target
NCT01858519 is a clinical trial that has completed, run by AbbVie. The registered enrollment target is 1,310 participants.
The verdict
NCT01858519 has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- 1,310 participants
- Enrollment target
Study Summary
This is a point prevalence study conducted entirely in the United States (US) to establish the prevalence of antibodies to hepatitis E virus (HEV) and other selected porcine viruses in cystic fibrosis (CF) patients receiving pancreatic enzyme replacement therapy (PERT) for pancreatic insufficiency compared with matched (age and region of residence) control patients with chronic medical conditions unexposed to PERT.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,310 participants |
| Start Date | 2013-08 |
| Est. Completion | 2016-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01858519
The ClinicalTrials.gov registry entry for NCT01858519 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,310 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01858519 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01858519 about?
NCT01858519 is a clinical study titled "Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement Therapy". This is a point prevalence study conducted entirely in the United States (US) to establish the prevalence of antibodies to hepatitis E virus (HEV) and other selected porcine viruses in cystic fibrosis (CF) patients receiving pancreatic enzyme replacement therapy (PERT) for pancreatic insufficiency c...
What is the current status of trial NCT01858519?
This trial is currently completed. The enrollment target is 1,310 participants. The study started on 2013-08. Estimated completion is 2016-09.
Who is sponsoring clinical trial NCT01858519?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.